London Stock Exchange

Report Date: August 29, 2025

Health Care/Pharmaceuticals

Business Description and Key Statistics

GSK plc is a global biopharma company. The Company?s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Website:	https://www.gsk.com/		
ICB Industry:	Health Care		
ICB Subsector: Pharmaceuticals			
Address:	980 Great West Road BRENTFORD TW8 9GS GBR		
Employees:	68,629		

	Current	YTY % Chg
Revenue LFY (M)	31,376	0.6
EPS Diluted LFY	0.62	-4.5
Market Value (M)	60,208	
Shares Outstanding LFY (000)	4,145,132	
Book Value Per Share	3.57	
EBITDA Margin %	28.10	
Net Margin %	17.6	
Long-Term Debt / Capital %	51.6	
Dividends and Yield TTM	0.63 - 4.27%	
Payout Ratio TTM %	45.8	
60-Day Average Volume (000)	8,798	
52-Week High & Low	16.71 - 12.64	
Price / 52-Week High & Low	0.87 - 1.15	
Beta 5-Year vs. S&P 500		

Price: 1,452.50

Price, Moving Averages & Volume



GSK plc is currently trading at 1,452.50 which is 10,172.3% above its 50 day moving average price of 14.14 and 10,201.4% above its 200 day moving average price of 14.10.

GSK:LN is currently 8,592.4% above its 52-week high price of 16.71 and is 11,391.3% above its 52-week low price of 12.64. Over the past 52weeks, GSK:LN is down 12.3% while on a calendar year-to-date basis it is up 7.9%.

The Relative Strength Index (RSI) indicator for GSK:LN is currently 54.23. An RSI value of 70 and above is considered overbought and 30 and below oversold.

Health Care/Pharmaceuticals

Price Performance, Technical Indicators & Risk Metrics

Price Performance	% Change	Difference vs FTSE 350	Technical Indicators	
1-Day %	-0.48	-0.12	50-Day Average Price	14.14
1-Week %	-2.68	-1.41	Price / 50-Day Average	1.03
4-Week %	2.43	2.10	200-Day Average Price	14.10
52-Week %	-12.34	-21.10	Price / 200-Day Average	1.03
Quarter-to-Date %	4.50	0.23	RSI - Relative Strength Index	54.23
Year-to-Date %	7.87	-3.56	Risk Metrics	
Last Month %	2.01	-1.91	Price Volatility	0.37
Last Quarter %	-4.92	-8.03	Sharpe Ratio	-0.01
Last Calendar Year %	-7.15	-12.70	Sortino Ratio	-0.02
			Beta 3-Year vs. S&P 500	
			Beta 5-Year vs. S&P 500	

Price: 1,452.50

5-Year Price Performance vs. FTSE 350



Current: 1.00 CAGR: 0.0%

Over the past five years, GSK plc's stock price is up 0.2% which is 52.8% below the FTSE 350 Index performance of 53.0% over the same period. GSK plc's cumulative annualized growth rate (CAGR) over the five year period has been 0.0% while that of the FTSE 350 Index has been 8.9%.

Over the past year, GSK plc's stock price performance of -12.3% has underperformed that of the FTSE 350 Index by 21.1%. On a year-to-date basis, GSK plc's stock price performance of 7.9% has underperformed the FTSE 350 Index by 3.6%.

Over the past week, GSK plc's stock price performance of -2.7% has underperformed that of the FTSE 350 Index by 1.4%.




Report Date: August 29, 2025

Health Care/Pharmaceuticals

Growth and Profitability Metrics

Historical Growth	3-Year	5-Year	10-Year	Profitability	Current	5-Year Average	10-Year Average
Revenues %	-3.6	-2.0	3.1	Gross Margin %	71.8	69.5	68.8
Revenues Per Share %	-5.7	-2.5	2.4	EBITDA Margin %	28.1	29.1	27.0
EBITDA %	-3.4	-0.1	-4.1	Pre-Tax Margin %	14.6	17.6	16.8
EPS Diluted %	-1.7	-0.4	3.1	Net Margin %	17.6	16.9	17.3
Free Cash Flow %	-16.8	-10.0	6.8	Return on Equity %	39.5	39.5	64.0
Cash from Operations %	-9.7	-4.4	6.6	Return on Capital %	19.5	16.1	19.2
Book Value %	-10.8	0.8	7.4	Return on Assets %	9.4	8.0	8.4

Price: 1,452.50



2022

GSK plc's cumulative annualized revenue growth rate over the charted period is -2.1%. This compares to cumulatative annualized growth of -3.6% over the past 3 years.

GSK plc's cumulative annualized EPS growth rate over the charted period is -18.8%. This compares to cumulatative annualized growth of -1.7% over the past 3 years.

GSK plc's net profit margin of 17.6% is 0.7% above the period's mean net margin of 16.9%. During the charted period, the observed net profit margin high and low were 20.6% and 14.7% respectively.

GSK plc's return on equity of 39.5% is 0.0% below the period's mean return on equity of 39.5%. During the charted period, the observed ROE high and low were 51.2% and 33.1% respectively.

38.8

32.2

2025

2021

2020

38.8

32.2




2023

2024



Report Date: August 29, 2025





GSK plc is trading at 10.73 times its EPS generated during the latest fiscal year. This multiple is below the historically observed median of 10.89, while high and low observations have been 13.28 and 8.60.

GSK plc is trading at a Price to Sales ratio of 1.89 based on sales generated during the latest fiscal year. This ratio is above the historically observed median ratio of 1.85, while high and low observations have been 2.41 and 1.42.

GSK plc is trading at a Price to Book ratio of 4.07 based on book value at the latest fiscal year end. This ratio is below the historically observed median of 4.33, while high and low observations have been 6.48 and 2.59.

GSK plc has a Free Cash Flow Yield of 7.80% based on free cash flow generated during the latest fiscal year. This value is below the historically observed median yield of 7.95%, while high and low observations have been 15.06 and 3.67.





						Conception of the second se	
Health Care/Pharmaceuticals		als	Price: 1,452.50		Report Date: August 29, 2025		
Dividen	ds Data						
Dividends	Per Share TTM	0.63 Pa	yout Ratio TTM %	45.80)%	Dividend Yield TTM %	4.27%
Rate	Ex Date	Record Date	Payment Date	Currency	Note		
0.160	14-08-2025	15-08-2025	09-10-2025	GBP			
0.160	15-05-2025	16-05-2025	10-07-2025	GBP			
0.160	20-02-2025	21-02-2025	10-04-2025	GBP			
0.150	14-11-2024	15-11-2024	09-01-2025	GBP			
0.150	15-08-2024	16-08-2024	10-10-2024	GBP			
0.150	16-05-2024	17-05-2024	11-07-2024	GBP			
0.160	22-02-2024	23-02-2024	11-04-2024	GBP			
0.140	16-11-2023	17-11-2023	11-01-2024	GBP			
0.140	17-08-2023	18-08-2023	12-10-2023	GBP			
0.140	18-05-2023	19-05-2023	13-07-2023	GBP			

GBP

GBP

13-04-2023

12-01-2023


Dividend Growth and Yield

23-02-2023

17-11-2022

0.138


0.138



24-02-2023

18-11-2022


GSK plc's trailing 12-month dividend per share is 0.62 and its dividend has grown at a cumulative annualized rate of -5.8% over the charted period. This compares to dividend growth of 5.00% over the past year and cumulative annualized growth of -4.70% over the past 3 years.




GSK plc's current dividend yield is 4.27% based on trailing 12 month dividends. The current yield is below the historically observed median of 4.54% and, over the charted time period, the observed high yield has been 6.72% and the observed low yield has been 3.22%.

Health Care/Pharmaceuticals


ICB Subsector Peer Comparisons



Price / EPS TTM




EPS 5-Year Growth Rate %




Price Change Last Calendar Year %


Price: 1,452.50



Price / Book Value




Revenue 5-Year Growth Rate %





Report Date: August 29, 2025



Health Care/Pharmaceuticals



Report Date: August 29, 2025

Abbreviations:

CAGR	- Cumulative annual growth rate.
EBIT	 Earnings before interest and taxes.
EBITDA	- Earnings before interest, taxes, depreciation & amortization.
LFY	- Last fiscal year
М	- Million
LON	- London Stock Exchange

Definitions:

Market Value - Weekly Price times latest Shares Outstanding times any applicable ADR factor.

Revenue - Sum of the last four quarters of Revenues.

Revenue Per Share - Sum of the last four quarters of Total Revenue divided by Weighted Average Shares Outstanding.

Normalized EPS LFY- EPS excluding non-recurring, non-operating items, fiscal year aligned TTM value.

60-Day Average Volume (000) - The average of the last 60 daily volume values in thousands of shares.

Price 52-Week High - The high closing price from the last 52 weeks of daily closing prices.

Price 52-Week Low - The low closing price from the last 52 weeks of daily closing prices.

Price / 52-Week High - Latest price divided by the high price from the past 52 weeks of daily closing prices.

Price / 52-Week Low - Latest price divided by the low price from the past 52 weeks of daily closing prices.

50-Day Average Price - Mean of last 50 daily closing prices.

200-Day Average Price - Mean of last 200 daily closing prices.

Price / 50-Day Average Price - Latest closing price divided by mean of last 50 daily closing prices, as a percentage.

Price / 200-Day Average Price - Latest closing price divided by mean of last 200 daily closing prices, as a percentage.

Relative Strength Index - Relative Strength Index or RSI measures the magnitude of gains over a given time period against the magnitude of losses over that period. The equation is RSI = 100 - 100 / (1 + RS) where RS = (total gains / n) / (total losses / n) and n = number of RSI periods. In this item, 14 days is used and one year of daily prices are considered. A value of 30 or below may imply oversold and 70 or above may imply overbought.

Price: 1,452.50

Price Volatility - The standard deviation of the last 20 days of daily closing prices.

Sharpe Ratio - The 5 year average of the excess monthly return over the risk - free rate(1 - month T - bill) over the 5 year standard deviation of the same series.

Sortino Ratio - The same calculation as the Sharpe Ratio but with positive excess returns set to zero for the standard deviation denominator, so only negative volatility weighs in.

Dividends Per Share TTM - Sum of the last four quarters of Dividends Per Share.

Payout Ratio - Dividends Per Share TTM divided by Normalized EPS TTM.

Dividend Yield TTM % - Sum of the last four quarter of Dividends Per Share divided by Weekly Price.

EBITDA - Sum of the last four quarters of EBITDA (Operating Income + Depreciation & Amortization).

Free Cash Flow - Sum of the last four quarters Net Cash from Operations minus Capital Expenditures (Purchase of Property, Plant & Equipment), from the Cash Flow Statement.

Book Value Per Share - Total Common Equity last quarter divided by Shares Outstanding last quarter.

Gross Margin % - Sum of the last four quarters Gross Profit divided by the sum of the last four quarters Revenues.

EBITDA Margin % - Sum of the last four quarters EBITDA divided by the sum of the last four quarters Revenues.

Pre-Tax Margin % - Sum of the last four quarters of Earnings Before Taxes divided by sum of the last four quarters Revenues.

Net Profit Margin % - Sum of the last four quarters of Normalized EPS divided by sum of the last four quarters Revenues Per Share.

Return on Equity % - Sum of the last four quarters of Normalized EPS divided by the average of the last four quarters Book Value.

Return on Capital % - Sum of the last four quarters of Normalized EPS divided by the average of the last four quarters Total Capital Per Share.

Return on Assets % - Sum of the last four guarters of Normalized EPS divided by the average of the last four guarters Total Assets Per Share.

Price / EPS TTM - Weekly Price divided by the sum of the last four quarters of Normalized EPS (capped at 99.9).

Price / Sales - Weekly Price divided by Revenues Per Share TTM.

Price / Book Value - Weekly Price divided by Book Value Per Share last quarter. Book Value Per Share is Total Common Equity last quarter divided by Shares Outstanding last quarter (capped at 49.9).

Free Cash Flow Yield % - Free Cash Flow Per Share TTM divided by Weekly Price.

Enterprise Value - Market Value plus Total Debt last year plus Preferred Equity last year minus Cash & Cash Equivalents last year.

Enterprise Value / Sales - Enterprise Value divided by the sum of the last four quarters of Revenue.

Enterprise Value / EBITDA - Enterprise Value divided by EBITDA TTM.

Enterprise Value / EBIT - Enterprise Value divided by trailing four quarters of Operating Income.

Enterprise Value / Free Cash Flow- Enterprise Value divided by the sum of the last four quarters of Free Cash Flow.

Russell 1000 Index - The largest 1,000 stocks by market cap, the index comprehensively covers the US large cap universe.

EPS 5-Year Growth Rate % is capped at 999.9%.

Revenue 5-Year Growth Rate % is capped at 999.9%.

Health Care/Pharmaceuticals

London Stock Exchange

Report Date: August 29, 2025

Price: 1,452.50

Disclaimer:

© 2025 London Stock Exchange Group plc and its applicable group undertakings (the "LSE Group"). The LSE Group includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, "FTSE Canada"), (4) MTSNext Limited ("MTSNext"), (5) Mergent, Inc. ("Mergent"), (6) FTSE Fixed Income LLC ("FTSE FI") and (7) The Yield Book Inc ("YB"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB. "FTSE®", "Russell®", "FTSE Russell®", "MTS®", "FTSE4Good®", "ICB®", "Mergent®", "The Yield Book®" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell indexes or data or the fitness or suitability of the FTSE Russell indexes or data for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell indexes or data is provided for information purposes only and is not a reliable indicator of future performance.

No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of the LSE Group nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing contained in this document or accessible through FTSE Russell indexes or data, including statistical data and industry reports, should be taken as constituting financial or investment advice or a financial promotion.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of the LSE Group. Use and distribution of the LSE Group data requires a licence from FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB, and/or their respective licensors.